Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
Description of Invention:
This invention comprises a number of novel anti-mycobacterial compositions, which offer to significantly improve the treatment of mycobacterial infection such as tuberculosis. Mycobacterium is a genus of bacteria encompassing a number of organisms, many of which are highly pathogenic in humans. The most well known of these are M. tuberculosis, which causes pulmonary tuberculosis, and M. leprae, which causes leprosy. Tuberculosis is a major worldwide problem, especially among HIV-infected and other immune-compromised individuals. Present treatments for tuberculosis often have toxic side effects or have limited utility because of the growing number of multi-drug resistant strains of M. tuberculosis. These newly discovered anti-mycobacterial compounds, which are analogs of thiatetracosanoate, have been shown effective in the treatment of mycobacterial infections and are relatively nontoxic. They may be given alone or in combination with standard anti-mycobacterial drugs and are valuable as antiseptics as well as therapeutics.
Inventors:
Clifton E. Barry III (NIAID) et al.
Patent Status:
DHHS Reference No. E-095-1994/0 --
U.S. Patent 5,610,198 issued 11 Mar 1997
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
